Qingdao Haier Biomedical Co., Ltd.
Address: No. 280, Fengyuan Road, High-tech Zone, Qingdao City, Shandong Province
Company website: https://www.haierbiomedical.com/cn?lang=zh_CN
Company Overview
Haier Biomedical, founded in 2005 and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2019 (stock code: 688139), is a digital scenario solution service provider for life science and medical innovation based on the transformation of the Internet of Things. The company aims to create the best user experience and provides comprehensive digital scenario solutions represented by smart laboratories, digital hospitals, smart public health, and smart blood use for life science users such as pharmaceutical companies, universities, and scientific research institutions, and medical and health users such as hospitals, disease control, blood stations, and grassroots public health. The company always adheres to technological leadership, promotes technological innovation, and leads industrial transformation. Since breaking through the low-temperature technology of biomedicine and breaking the foreign monopoly, the company has continued to invest in the research and development of new technologies. At present, it has formed eight major technical platforms such as automation, separation, consumables, and reagents. It has successively broken through core technologies such as high-precision identification, positioning, and grasping technology, high-precision frequency conversion control technology, visual recognition technology, and laboratory consumables manufacturing technology, and has laid out microbial culture, environmental simulation, centrifugation, polymer materials and other fields, and accelerated the strengthening, expansion, and extension of its own business layout. At the same time, the company actively integrates into national strategies such as science and technology power, digital China, and healthy China, takes the lead in integrating emerging technologies such as the Internet of Things, artificial intelligence, and cloud computing, and pioneers the launch of digital scene comprehensive solutions represented by smart blood use and smart vaccination, and continues to expand to smart laboratories, in-hospital drug automation, public health physical examinations and other scenes, leading the digital transformation of the biomedical industry. The company has always adhered to the vision of "making life better", and its products and solutions have been applied in more than 140 countries and regions around the world. In the domestic market, it covers tens of thousands of end users such as hospitals, biotechnology companies, university research institutions, disease control, plasma stations, and testing institutions, including the General Hospital of the People's Liberation Army (301 Hospital), Shanghai Ruijin Hospital, WuXi AppTec, Shanghai Fudan University, China Center for Disease Control and Prevention, Hualan Bio, Hengrui Medicine, Fosun Pharma and many other well-known institutions; in the international market, the network layout is constantly improving, the localization layout is strengthened, and it maintains long-term and continuous cooperation with more than 40 international organizations such as the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF).